Michael P. Johnson

发表

[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand

A. Carr, Michael P. Johnson, Barry W. Siegel, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Reduction in brain serotonin markers by α-ethyltryptamine (Monase)

Michael P. Johnson, D. Nichols, Xuemei Huang, 1991 .

Metabotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

S. Nakanishi, R. Duvoisin, R. Shigemoto, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine

Michael P. Johnson, D. Nichols, 1990, Pharmacology Biochemistry and Behavior.

Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists 1 Published on the World Wide Web on 4 February 1999. 1

G. Kelly, M. Chamberlain, Michael P. Johnson, 1999, Brain Research.

[125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex

C. Mathis, Michael P. Johnson, A. Shulgin, 1990, Pharmacology Biochemistry and Behavior.

Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain struct

D. McKinzie, D. Clawson, S. Atwell, 2015, Journal of medicinal chemistry.

Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis

K. Westlund, T. McNearney, R. Kline, 2014, Molecular pain.

Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP)

Kirk W. Johnson, K. Johnson, R. Benschop, 2018, Cephalalgia : an international journal of headache.

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

C. Swanson, M. Bures, D. Schoepp, 2005, Nature Reviews Drug Discovery.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

E. Nisenbaum, D. McKinzie, D. Schoepp, 2005, Psychopharmacology.

PET ligands [18F]LSN3316612 and [11C]LSN3316612 quantify O-linked-β-N-acetyl-glucosamine hydrolase in the brain

S. Zoghbi, J. Liow, R. Gladding, 2020, Science Translational Medicine.

Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue

Michael P. Johnson, D. Nichols, Xuemei Huang, 1991, Pharmacology Biochemistry and Behavior.

Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain.

J. Schkeryantz, Michael P Johnson, A. Kingston, 2007, Journal of medicinal chemistry.

Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis

J. McDougall, M. Chambers, J. Oskins, 2011, PAIN.

Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.

Kirk W. Johnson, G. Stephenson, J. Shah, 2013, ACS medicinal chemistry letters.

Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.

Michael W Tidwell, M. Chambers, J. Oskins, 2013, Journal of medicinal chemistry.

The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.

M. Chambers, Michael P Johnson, S. Hollinshead, 2014, Bioorganic & medicinal chemistry letters.

Discovery and optimization of novel purines as potent and selective CB2 agonists.

Michael W Tidwell, M. Chambers, S. Hollinshead, 2012, Bioorganic & medicinal chemistry letters.

An Animal Model of Emotional Blunting in Schizophrenia

T. Vladusich, J. D. den Boer, J. Doorduin, 2007, PloS one.

Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats

Kirk W. Johnson, V. Wroblewski, Michael P. Johnson, 2019, Cephalalgia : an international journal of headache.

Metabotropic glutamate receptors in GtoPdb v.2021.3

S. Nakanishi, R. Duvoisin, R. Shigemoto, 2021, IUPHAR/BPS Guide to Pharmacology CITE.

Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists

D. Schoepp, B. Clark, J. Tizzano, 2002, Neuroscience Letters.

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.

D. Schoepp, T. Large, M. Baez, 2003, Journal of medicinal chemistry.

Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists

M. Geyer, L. Gold, C. W. Callaway, 2005, Psychopharmacology.

Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration

Michael P. Johnson, D. Nichols, 1989, Pharmacology Biochemistry and Behavior.

Group II Metabotropic Glutamate Receptors (mGlu2 and mGlu3)

D. Schoepp, Michael P Johnson, Michael P. Johnson, 2008 .

SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide.

D. Schoepp, D. Barda, Michael P Johnson, 2004, Bioorganic & medicinal chemistry letters.

Innovative drug development for headache disorders: glutamate

Kirk W. Johnson, N. Ramadan, E. Nisenbaum, 2008 .

Group II Metabotropic Glutamate Receptor Modulation of DOI-induced c-fos mRNA and Excitatory Responses in the Cerebral Cortex

E. Nisenbaum, L. Nisenbaum, Michael P. Johnson, 2003, Neuropsychopharmacology.

Assessment of the role of α-methylapinine in the neurotoxicity of MDMA

D. E. Nichols, G. K. Yim, Michael P Johnson, 1991, Pharmacology Biochemistry and Behavior.

Behavioral Recovery Patterns in Rats Receiving the NMDA Receptor Antagonist MDL 100,453 Immediately Post-Stroke

Michael P. Johnson, C. Markgraf, Mary V Bickers, 1997, Pharmacology Biochemistry and Behavior.

Synthesis and Pharmacological Examination of 1‐(3‐Methoxy‐4‐methylphenyl)‐2‐aminopropane and 5‐Methoxy‐6‐methyl‐2‐aminoindan: Similarities to 3,4‐(Methylenedioxy)methamphetamine (MDMA).

Michael P. Johnson, R. Oberlender, S. Frescas, 1991 .

5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine

Michael P. Johnson, R. Oberlender, D. Nichols, 1991, Pharmacology Biochemistry and Behavior.

Nonneurotoxic Tetralin and Indan Analogues of 3,4‐(Methylenedioxy)amphetamine (MDA).

R. M. Riggs, Michael P. Johnson, W. Brewster, 1990 .

Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.

Kirk W. Johnson, M. Blanco, D. Benesh, 2017, Bioorganic & medicinal chemistry letters.

Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis

J. McDougall, M. Chambers, J. Oskins, 2011, PAIN.